OXILAN-300
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXILAN-300 is an injectable small-molecule product approved by Guerbet in 1995 for an undisclosed indication(s). The specific mechanism of action and therapeutic class remain proprietary or unavailable in this dataset.
LOE Approaching
Product is in late commercial lifecycle with moderate competitive pressure (30/100), indicating a consolidating team focused on market defense rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OXILAN-300 currently has zero linked job openings, reflecting a mature product with a stable but not expanding commercial footprint. Careers on this team prioritize operational efficiency and market maintenance over growth and innovation.
Brand ManagerMarket Access Manager
Worked on OXILAN-300 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.